EFSPI regulatory statistics workshop 2024: analysis of registrations

Author

Kaspar Rufibach

Published

Invalid Date

Data status

Data as of 2025-05-09 at 17:46:33.

Registrations by type of institution

Registrations by background

Registrations by institution

Registrations of regulatory colleagues

Registrations of HTA colleagues

Registrations by countries

Registrations by countries - map

Registrations by geographic region

Registrations by mode of attendance

Registrations by mode of attendance and F2F block booking status

Boehringer Ingelheim (N=17) Novartis (N=234) Roche (N=104) Total (N=355)
mode
   Face-to-face (280 Euro) 4 (23.5%) 103 (44.0%) 66 (63.5%) 173 (48.7%)
   Virtual (70 Euro) 13 (76.5%) 131 (56.0%) 38 (36.5%) 182 (51.3%)

Registrations by mode of attendance and virtual block booking status

Bayer (N=61) BMS (N=49) Novo Nordisk (N=77) Total (N=187)
mode
   Face-to-face (280 Euro) 2 (3.3%) 6 (12.2%) 7 (9.1%) 15 (8.0%)
   Virtual (70 Euro) 59 (96.7%) 43 (87.8%) 70 (90.9%) 172 (92.0%)

Registration waived yes / no

Registrations by meals and wine tasting

No-shows among those who registered for face-to-face participation

Novartis (N=103) Roche (N=66) Total (N=169)
noshow
   show 90 (87.4%) 58 (87.9%) 148 (87.6%)
   no show 13 (12.6%) 8 (12.1%) 21 (12.4%)